Robert Carnahan

Infectious diseases pose a significant global health challenge, accounting for a substantial proportion of deaths worldwide, according to recent data from the World Health Organization. Vanderbilt’s Life Science Showcase: Advancing Innovation in Infectious Diseases held on July 18 emphasized the vital importance of advancing research and innovation to combat these persistent threats. Read More

Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself. Read More

Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization. Read More

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19. Read More

A monoclonal antibody cocktail against the COVID-19 virus discovered at VUMC is the first non-vaccine modified to demonstrate the prevention of COVID-19 in a clinical trial of more than 5,000 participants. The antibody treatment could afford up to 12 months of protection from COVID-19, and preliminary laboratory findings also suggest that it can neutralize the delta variant. Read More

Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes.  Read More

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. Read More

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read More

From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic. Read More

Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19. Read More

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19. Read More

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus. Read More